$ 8.76
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of FENC is 14 and suggests 60% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
